N/A
Completed N=847
Safety and Efficacy of Relestat Ophthalmic Solution 0.05% for Allergic Conjunctivitis in Korea
Conjunctivitis, Allergic
Source: ClinicalTrials.gov NCT01987765 ↗
Enrolled (actual)
847
Serious AEs
0.0%
Results posted
Apr 2014
Primary outcomePrimary: Percentage of Patients Reporting Adverse Events — 0.13 Percentage of Patients
Summary
This study is a Post-Marketing Surveillance study in Korea to evaluate the safety and efficacy of Relestat Ophthalmic Solution 0.05% in patients with allergic conjunctivitis who are treated with Relestat as standard of care in clinical practice.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Percentage of Patients Reporting Adverse Events |
0.13 | — |
| PRIMARY Change From Baseline in Eye Symptoms Total Score on a 4-Point Scale |
5.58; -4.06 | — |
Eligibility Criteria
Inclusion Criteria
- Patients with Allergic Conjunctivitis treated with Relestat Ophthalmic Solution in clinical practice.
Exclusion Criteria
- None.
Data sourced from ClinicalTrials.gov (NCT01987765). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.